Riechelmann H, et al. Oral. Oncol. (2008) cited as Ref 555 in DOI: 10.1038/s41392-020-0110-5 (Q9818)

From Wikibase.slis.ua.edu
Revision as of 22:04, 20 May 2020 by Admin (talk | contribs) (‎Created claim: Property:P93: Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma, #quickstatements; #temporary_batch_1590010982689)
Jump to navigation Jump to search
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
Language Label Description Also known as
English
Riechelmann H, et al. Oral. Oncol. (2008) cited as Ref 555 in DOI: 10.1038/s41392-020-0110-5
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8

    Statements

    Riechelmann H
    0 references
    0 references
    2008
    0 references
    Oral. Oncol.
    0 references
    44
    0 references
    Phase I trial with the CD44v6-targeting immunoconjugate bivatuzumab mertansine in head and neck squamous cell carcinoma (English)
    0 references